Comparative Evidence Needs Earlier Consideration In Drug Development Process – Novartis Exec
As comparative effectiveness research grows in importance, drug manufacturers need to factor it, as well as payer evidence needs, into product development decisions, Novartis Head of Comparative Effectiveness Research and Communications Amy Rudolph says.
You may also be interested in...
Authors of a Health Affairs article find the effect of active drugs versus placebo has declined in controlled trials over time, suggesting to them that more attention should be focused on understanding the clinical value of existing treatments, including establishing equivalence of efficacy and focusing on differences in safety, cost and tolerability.
Execs from GlaxoSmithKline and OptumInsight offer insight on the need for pharma companies to develop strategies that account for the growing role comparative effectiveness research is playing in reforming health care, a role that will continue despite what happens in legal and legislative circles in Washington, D.C.
Grants will help inform Methodology Committee activities; member Clyde Yancy sees committee’s work as setting the bar for how to conduct patient-centered outcomes research.